November 25, 2016 - By Pete Kolinski · 0 Comments
The stock of Becton Dickinson & Company (NYSE:BDX) registered a decrease of 17.45% in short interest. BDX’s total short interest was 3.90M shares in November as published by FINRA. Its down 17.45% from 4.72M shares, reported previously. With 995,000 shares average volume, it will take short sellers 4 days to cover their BDX’s short positions. The short interest to Becton Dickinson & Company’s float is 1.84%. About 278,600 shares traded hands. Becton Dickinson and Co (NYSE:BDX) has risen 5.38% since April 22, 2016 and is uptrending. It has underperformed by 0.03% the S&P500.
Becton, Dickinson and Company is a global medical technology firm engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The company has a market cap of $36.50 billion. The Firm operates through two business divisions: BD Medical, which consists of Diabetes Care, Medication and Procedural Solutions, Medication Management Solutions, Pharmaceutical Systems and Respiratory Solutions business units, and BD Life Sciences, which consists of Preanalytical Systems, Diagnostic Systems and Biosciences business units. It has a 37.94 P/E ratio.
Insitutional Activity: The institutional sentiment increased to 0.9 in 2016 Q2. Its up 0.01, from 0.89 in 2016Q1. The ratio is positive, as 50 funds sold all Becton Dickinson and Co shares owned while 332 reduced positions. 63 funds bought stakes while 276 increased positions. They now own 178.24 million shares or 0.47% less from 179.07 million shares in 2016Q1.
The New York-based Guardian Life Of America has invested 0.01% in Becton Dickinson and Co (NYSE:BDX). Asset Management accumulated 1,284 shares or 0.04% of the stock. Whittier Of Nevada last reported 7,145 shares in the company. Millennium Mgmt holds 0.02% of its portfolio in Becton Dickinson and Co (NYSE:BDX) for 52,555 shares. The North Carolina-based Ncm Mngmt Group has invested 0.79% in Becton Dickinson and Co (NYSE:BDX). Alyeska Invest Group Lp has 585,756 shares for 1.01% of their US portfolio. Ghp has 3,226 shares for 0.12% of their US portfolio. Tdam Usa Incorporated holds 0.2% of its portfolio in Becton Dickinson and Co (NYSE:BDX) for 24,304 shares. Aberdeen Asset Public Limited Liability Company Uk has 69,282 shares for 0.04% of their US portfolio. Morgan Stanley holds 0.04% or 695,864 shares in its portfolio. Moreover, Ballentine Prtnrs Ltd Liability Corp has 0.02% invested in Becton Dickinson and Co (NYSE:BDX) for 1,385 shares. Tealwood Asset Mngmt has 9,530 shares for 0.73% of their US portfolio. Pineno Levin & Ford Asset Mgmt has 29,953 shares for 2.63% of their US portfolio. Cubist Systematic Strategies Ltd Limited Liability Company reported 8,613 shares or 0.08% of all its holdings. Canada Pension Plan Board owns 35,573 shares or 0.02% of their US portfolio.
Insider Transactions: Since June 7, 2016, the stock had 0 buys, and 5 insider sales for $10.28 million net activity. The insider Tharby Linda M sold $2.07M. 29,367 shares were sold by COHEN GARY M, worth $5.19 million on Thursday, August 11. On Monday, June 13 Gallagher John E sold $328,019 worth of the stock or 1,931 shares. $1.82 million worth of shares were sold by Sichak Stephen on Friday, November 4. $857,250 worth of Becton Dickinson and Co (NYSE:BDX) was sold by Shabshab Nabil on Tuesday, June 7.
Out of 10 analysts covering Becton Dickinson (NYSE:BDX), 4 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 40% are positive. Becton Dickinson has been the topic of 16 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Friday, August 5 by UBS. Citigroup initiated the shares of BDX in a report on Thursday, November 12 with “Neutral” rating. Citigroup downgraded it to “Sell” rating and $165 target price in Friday, September 23 report. The stock of Becton Dickinson and Co (NYSE:BDX) has “Sector Perform” rating given on Thursday, February 4 by RBC Capital Markets. The firm has “Equal-Weight” rating by Morgan Stanley given on Monday, January 4. The firm has “Hold” rating by Evercore given on Wednesday, January 6. The company was maintained on Monday, August 10 by Deutsche Bank. On Thursday, February 11 the stock rating was upgraded by Deutsche Bank to “Buy”. The company was maintained on Friday, August 7 by RBC Capital Markets. The stock of Becton Dickinson and Co (NYSE:BDX) earned “Neutral” rating by Citigroup on Thursday, February 4.
Becton, Dickinson and Company (BD), incorporated in November 1906, is a global medical technology firm engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Firm operates through two business divisions: BD Medical and BD Life Sciences. The Firm sells its products outside the United States, including hypodermic needles and syringes; insulin syringes and pen needles; BD Hypak brand prefillable syringe systems; infusion therapy products, including Alaris infusion pumps; pharmacy automation equipment; respiratory equipment and disposable products; BD Vacutainer brand blood collection products; diagnostic systems and laboratory equipment and products, and flow cytometry instruments and reagents. The Firm has its manufacturing activities outside the United States in Bosnia and Herzegovina, Brazil, Canada, China, Dominican Republic, France, Germany, Hungary, India, Ireland, Italy, Japan, Mexico, the Netherlands, Singapore, Spain and the United Kingdom.
More recent Becton Dickinson and Co (NYSE:BDX) news were published by: Prnewswire.com which released: “Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt …” on November 16, 2016. Also Reuters.com published the news titled: “BRIEF-Becton, Dickinson and Co announces tender offers for outstanding deb…” on November 16, 2016. Seekingalpha.com‘s news article titled: “Becton, Dickinson & Co. (BDX) Q4 2016 Results – Earnings Call Transcript” with publication date: November 03, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Pete Kolinski